Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Velocity Medical Solutions, Atlanta, Georgia.
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1099-107. doi: 10.1016/j.ijrobp.2014.08.017. Epub 2014 Oct 13.
To quantify the relationship between bone marrow (BM) response to radiation and radiation dose by using (18)F-labeled fluorodeoxyglucose positron emission tomography [(18)F]FDG-PET standard uptake values (SUV) and to correlate these findings with hematological toxicity (HT) in cervical cancer (CC) patients treated with chemoradiation therapy (CRT).
Seventeen women with a diagnosis of CC were treated with standard doses of CRT. All patients underwent pre- and post-therapy [(18)F]FDG-PET/computed tomography (CT). Hemograms were obtained before and during treatment and 3 months after treatment and at last follow-up. Pelvic bone was autosegmented as total bone marrow (BMTOT). Active bone marrow (BMACT) was contoured based on SUV greater than the mean SUV of BMTOT. The volumes (V) of each region receiving 10, 20, 30, and 40 Gy (V10, V20, V30, and V40, respectively) were calculated. Metabolic volume histograms and voxel SUV map response graphs were created. Relative changes in SUV before and after therapy were calculated by separating SUV voxels into radiation therapy dose ranges of 5 Gy. The relationships among SUV decrease, radiation dose, and HT were investigated using multiple regression models.
Mean relative pre-post-therapy SUV reductions in BMTOT and BMACT were 27% and 38%, respectively. BMACT volume was significantly reduced after treatment (from 651.5 to 231.6 cm(3), respectively; P<.0001). BMACT V30 was significantly correlated with a reduction in BMACT SUV (R(2), 0.14; P<.001). The reduction in BMACT SUV significantly correlated with reduction in white blood cells (WBCs) at 3 months post-treatment (R(2), 0.27; P=.04) and at last follow-up (R(2), 0.25; P=.04). Different dosimetric parameters of BMTOT and BMACT correlated with long-term hematological outcome.
The volumes of BMTOT and BMACT that are exposed to even relatively low doses of radiation are associated with a decrease in WBC counts following CRT. The loss in proliferative BM SUV uptake translates into low WBC nadirs after treatment. These results suggest the potential of intensity modulated radiation therapy to spare BMTOT to reduce long-term hematological toxicity.
通过使用放射性核素标记的氟脱氧葡萄糖正电子发射断层扫描术(18F-FDG-PET)标准摄取值(SUV),定量分析骨髓(BM)对放射治疗的反应与放射剂量之间的关系,并将这些结果与接受放化疗的宫颈癌(CC)患者的血液学毒性(HT)相关联。
17 名诊断为 CC 的女性患者接受了标准剂量的放化疗。所有患者均在治疗前后进行了(18)F-FDG-PET/计算机断层扫描(CT)检查。在治疗前、治疗期间和治疗后 3 个月以及最后一次随访时获取全血细胞计数(Hemogram)。对骨盆骨进行自动分割,作为总骨髓(BMTOT)。根据 SUV 大于 BMTOT 的平均 SUV 值来勾画活性骨髓(BMACT)。计算每个区域接受 10、20、30 和 40Gy 的体积(V)(分别为 V10、V20、V30 和 V40)。创建代谢体积直方图和体素 SUV 图响应图。通过将 SUV 体素分为 5Gy 的放射治疗剂量范围,计算治疗前后 SUV 的相对变化。使用多元回归模型研究 SUV 下降、放射剂量与 HT 之间的关系。
BMTOT 和 BMACT 的平均治疗前后 SUV 相对降低率分别为 27%和 38%。治疗后 BMACT 体积明显减少(分别从 651.5cm3减少到 231.6cm3;P<0.0001)。BMACT V30 与 BMACT SUV 减少显著相关(R2=0.14;P<0.001)。BMACT SUV 的减少与治疗后 3 个月(R2=0.27;P=0.04)和最后一次随访(R2=0.25;P=0.04)时白细胞(WBC)计数的减少显著相关。BMTOT 和 BMACT 的不同剂量学参数与长期血液学结果相关。
即使暴露于相对较低剂量的辐射,BMTOT 和 BMACT 的体积也与 CRT 后白细胞计数下降有关。增殖性 BM SUV 摄取的丧失导致治疗后白细胞计数的低值。这些结果表明,调强放疗有可能保护 BMTOT,以减少长期血液学毒性。